2023-08-31T08:12:44-07:00 2022-12-31 770581023 Stoltey & Associates 4643 Kennington Dr Santa Maria CA 93455 990 2022-01-01 951684086 Sansum Diabetes Research Institute SANS 8056827638 2219 Bath Street Santa Barbara CA 93105 Ellen Goodstein Executive Dir. 2023-08-31 true Ellen Goodstein 999009999 true Brad A Stoltey P00241354 8056895880 X 2 AAL1 IAL1 FAL1 2022 2023-04-26 12:10:37Z Ellen Goodstein 2219 Bath Street Santa Barbara CA 93105 9236499 false X WWW.Sansum.Org X 1944 CA Dedicated to improving the lives of people impacted by diabetes through research, education and care. 19 19 112 42 0 3496686 5265574 3199263 2570436 4678866 335709 100657 -17307 11475472 8154412 0 0 3567551 3893191 0 767223 1703978 1775967 5271529 5669158 6203943 2485254 20925060 22174581 520930 1216310 20404130 20958271 Dedicated to improving the lives of people impacted by diabetes through research, education and care. false false 3129122 2197238 Research:RESEARCH TYPE 1 DIABETES:SDRI IS COMMITTED TO RESEARCH TO IMPROVE THE LIVES OF PEOPLE IMPACTED BY DIABETES IN ALL FORMS. FOR OVER A DECADE, SDRI HAS BEEN A GLOBAL LEADER IN THE DEVELOPMENT OF THE ARTIFICIAL PANCREAS (AP), PARTNERING WITH SUCH ILLUSTRIOUS INSTITUTIONS AS HARVARD UNIVERSITY, UNIVERSITY OF CALIFORNIA, SANTA BARBARA, MAYO CLINIC, MOUNT SINAI MEDICAL CENTER AND THE UNIVERSITY OF VIRGINIA, TO NAME JUST A FEW. THE GOAL OF THE AP SYSTEM IS TO PROVIDE AUTOMATED GLUCOSE REGULATION THROUGH CONTROLLED INSULIN DELIVERY IN RESPONSE TO DETECTED PATTERNS OF CHANGE. SDRIS ARTIFICIAL PANCREAS PROGRAM PROVIDES TRAINING AND SUPPORT FOR PATIENTS WITH TYPE 1 DIABETES WHO HAVE BEEN PRESCRIBED THIS TREATMENT BY THEIR PHYSICIAN OR AS PART OF ONE OF OUR RESEARCH STUDIES. SDRIS CERTIFIED TRAINERS MEET WITH PATIENTS ONE-ON-ONE TO TRAIN AND THEN MONITOR THEIR USE OF THIS NEW TECHNOLOGY. APPOINTMENTS INCLUDE EDUCATION ON GLUCOSE MONITORING, INSULIN SENSITIVITY FACTORS, AND OVERALL WELL-BEING. SDRI IS DOING GROUNDBREAKING RESEARCH, FUNDED BY THE NIH, STUDYING AUTOMATED INSULIN DELIVERY IN PREGNANT WOMEN WITH TYPE 1 DIABETES. IT IS A FIRST-OF-ITS-KIND STUDY IN COLLABORATION WITH JOHN A. PAULSON SCHOOL OF ENGINEERING AND APPLIED SCIENCES AT HARVARD UNIVERSITY, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, AND THE MAYO CLINIC. SDRI SCIENTISTS ALSO ENGAGE IN RESEARCH AND CLINICAL STUDIES TESTING NEW DEVICES AND MEDICATION AS WELL AS INVESTIGATOR-INITIATED RESEARCH DESIGNED TO UNDERSTAND THE DIABETES PROCESS AND OPTIMIZE TREATMENT. RECENTLY, ONE OF OUR RESEARCH PROGRAMS CONTRIBUTED TO FDA APPROVAL OF THE OMNIPOD 5 AP SYSTEM FOR PATIENTS WITH TYPE 1 DIABETES. SDRI CONDUCTED OVER A DOZEN DEVICE RESEARCH TRIALS IN 2022, LOOKING AT THE EFFICACY OF CONTINUOUS GLUCOSE MONITORING, AUTOMATED INSULIN DELIVERY SYSTEMS, AND KETONE MONITORING SYSTEMS.RESEARCH TYPE 2 DIABETES:UNDER THE LEADERSHIP OF OUR CHIEF SCIENTIFIC OFFICER, DR. SAMUEL KLEIN, SDRI HASDEVELOPED A NEW PROGRAM IN THE SCIENCE OF PRECISION METABOLISM. THIS RESEARCH INITIATIVE WILL PROVIDE A BETTER UNDERSTANDING OF THE MECHANISMS RESPONSIBLE FOR THE METABOLIC ALTERATIONS (E.G., INSULIN RESISTANCE, ALTERED HORMONAL RESPONSES TO MEAL INGESTION, ADVERSE BLOOD LIPIDS, INFLAMMATION IN FAT TISSUE) ASSOCIATED WITH CARDIOMETABOLIC DISEASES AND HOW SPECIFIC NUTRITIONAL INTERVENTIONS CAN IMPROVE METABOLIC HEALTH AND DECREASE THE RISK OF COMPLICATIONS. THIS RESEARCH GOES BEYOND THE IMPORTANCE OF DIET IN MAINTAINING BLOOD GLUCOSE CONTROL. IN 2021, SDRI ESTABLISHED THE SANTA BARBARA NUTRITION HEALTH COALITION. THE OVERARCHING GOAL OF THIS COALITION IS TO IMPROVE THE HEALTH AND WELL-BEING OF PEOPLE AT HIGH RISK FOR CARDIOVASCULAR AND METABOLIC DISEASES LIVING IN SANTA BARBARA COUNTY, BY DEVELOPING AND IMPLEMENTING INNOVATIVE COMMUNITY-BASED, AND EVIDENCE-BASED NUTRITION INTERVENTION PROGRAMS.46% OF THE PEOPLE LIVING IN SANTA BARBARA ARE LATINO AND ARE DISPROPORTIONATELY BURDENED BY OBESITY AND TYPE 2 DIABETES. TO COMBAT THIS EPIDEMIC, SDRI LAUNCHED A RESEARCH PROGRAM IN 2022 TO EVALUATE THE CLINICAL EFFICACY, ACCEPTANCE, AND POTENTIAL DISSEMINATION OF AN INNOVATIVE, CULTURALLY APPROPRIATE DIET INTERVENTION PROGRAM DEVELOPED BY SDRI INVESTIGATORS AND COLLABORATORS IN SOCIOECONOMICALLY DISADVANTAGED LATINO ADULTS WITH OBESITY AND DIABETES. 896812 327073 EDUCATION & COMMUNITY OUTREACH:SDRI CONDUCTS MULTI-FACETED EDUCATION SERIES THROUGHOUT THE COMMUNITY TO RESIDENTS WITH OR AT RISK OF DIABETES. THIS INCLUDES CLASSES AIMED AT CERTAIN TARGET POPULATIONS. TO HELP WOMEN WHOSE PREGNANCIES ARE COMPLICATED BY DIABETES, SDRI OFFERS EDUCATION FOR BEFORE, DURING, AND AFTER PREGNANCY TO GIVE WOMEN WITH DIABETES THE SAME CHANCE OF BIRTHING A HEALTHY BABY AS WOMEN WITHOUT DIABETES. AT SDRI, OUR TEAM IS COMMITTED TO IMPROVING HEALTH OUTCOMES FOR UNDERSERVED POPULATIONS. A KEY ELEMENT OF SDRIS EFFORTS INCLUDE HIRING BILINGUAL COMMUNITY HEALTH WORKERS (CHW) WHO SERVE A CRITICAL ROLE IN BUILDING TRUST AND RAPPORT WITHIN THE LOCAL LATINO POPULATION. ADDITIONALLY, CHW PROVIDE MULTI-LINGUAL NUTRITION EDUCATION, TRAINING ON TECHNOLOGY TO BETTER MANAGE DIABETES, CONDUCTING HEALTH SCREENINGS, RECRUITING STUDY PARTICIPANTS, AND MAINTAINING COMMUNICATION WITH KEY COMMUNITY ORGANIZERS TO PROMOTE SDRIS HEALTH EDUCATION PROGRAMS. THE IMPORTANT WORK PERFORMED BY SDRIS CHW ULTIMATELY HELPS TO REDUCE THE RATE OF TYPE 2 DIABETES AND PREVENT FUTURE GENERATIONS FROM DEVELOPING TYPE 2 DIABETES.SDRIS VEGGIE IQ PROGRAM IS A MODULE-BASED CURRICULUM THAT ENCOURAGES COMMUNITY YOUTH SCIENTISTS ACROSS GRADES K THROUGH 12 TO USE SCIENCE AND TECHNOLOGY TO DISCOVER THE IMPORTANT LINKS BETWEEN DIET AND HEALTH. SDRI CREATED SIX MODULES AND AN ONLINE PLATFORM WHERE TEACHERS AND ADMINISTRATORS CAN ACCESS LESSON PLANS AND LESSON VIDEO DOWNLOADS, ALONG WITH A MENU OF INTERACTIVE ACTIVITIES TAILORED TO DIFFERENT GRADE LEVELS. IN 2022 ALONE, VEGGIE IQ WAS FIRST LAUNCHED IN 32 CLASSROOMS AND INVOLVED 700 STUDENTS IN GRADES K-8. VEGGIE IQ CONTINUED AS A TWO CYCLE, 8-WEEK SUMMER PROGRAM FOR TEENS, GRADES 9-11, IN SANTA BARBARA AND LOMPOC. BOTH PROGRAMS WERE OVERWHELMINGLY SUCCESSFUL FOR ALL AGES.SDRI RECOGNIZED THE NEED FOR SENIORS IN OUR COMMUNITY WHO WANTED TO INTEGRATE DIABETES TECHNOLOGY INTO THEIR DAILY LIVES, BUT FELT UNPREPARED TO MANAGE THIS ON THEIR OWN. RESPONDING TO THIS NEED, SDRI CREATED A SENIOR EDUCATION PROGRAM THAT CONSISTED OF SIX SESSIONS, INCLUDING FOUR ONE-HOUR CLASSES WITH OUR CERTIFIED DIABETES CARE AND EDUCATION SPECIALIST (CDCES)/NURSE PRACTITIONER. CLASSES, OFFERED IN BOTH ENGLISH AND SPANISH, WERE COMPRISED OF ONLY FOUR TO FIVE PARTICIPANTS AND FOCUSED ON TRAINING SENIORS ABOUT THE NEW TECHNOLOGY WHILE PROVIDING PERSONAL SUPPORT WHEN TRANSITIONING TO NEW TECHNOLOGY. THE AIM OF THE PROGRAM IS THAT ALL PARTICIPANTS ARE COMFORTABLE USING THESE DEVICES ON THEIR OWN. THROUGH EFFECTIVE USE OF THIS TECHNOLOGY, OUR PATIENTS SPEND LESS TIME MANAGING THEIR DIABETES, AND MORE TIME ENJOYING LIFE. IN 2022, SDRI SUCCESSFULLY SERVED 120 SENIOR PARTICIPANTS. 98353 46125 CARE:SDRI PROVIDED CLINICAL CARE IN 3 AREAS: DIABETES IN PREGNANCY, PEDIATRIC CARE ANDADULT ENDOCRINOLOGY. IN THE LAST YEAR ALONE, OUR STAFF HAVE HELPED OVER 105 WOMENNAVIGATE THE DIFFICULT ROAD OF PREGNANCY COMPLICATED BY DIABETES IN ORDER TO DELIVERHEALTHY BABIES. IT WASNT TOO LONG AGO THAT WOMEN WITH DIABETES WERE TOLD NOT TO HAVE CHILDREN GIVEN THE RISK OF POSSIBLE BIRTH DEFECTS. OUR LATE CHIEF SCIENTIFIC OFFICER, DR. LOIS JOVANOVIC, DEVELOPED PROTOCOLS THAT HELPED WOMEN WITH DIABETES WORLDWIDE GIVE BIRTH TO HEALTHY BABIES. HER GROUNDBREAKING WORK CONTINUES TODAY. OUR DIABETES AND PREGNANCY CLINICAL CARE PROGRAM SUPPORTS WOMEN WITH EITHER TYPE 1, TYPE 2, OR GESTATIONAL DIABETES. OUR PEDIATRIC DEPARTMENT SPECIALIZES IN WORKING WITH CHILDREN AND TEENAGERS, SUPPORTING PATIENTS WITH ARTIFICIAL PANCREAS TECHNOLOGY, GLUCOSE CONTROL, AND INSULIN PUMPS. OUR PHYSICIANS CARE FOR BOTH TYPE 1 AND TYPE 2 DIABETES AS WELL AS OTHER ENDOCRINE ISSUES. 4124287 true true false false false false false false false true true false false true true true true false false false false false false false true false false false false true false false false false false false false false true false false false false false false false false true 165 0 true 112 true false false false false false false false 0 false false false false false false false X 19 19 false false false false false false false true true false false true true true true true true true true false CA X X CFO 8056827638 2219 Bath Street Santa Barbara CA 93105 David Kerr Director of Research & Innovation 40.00 0.00 313621 0 30734 Kristin Castorino DO Research Physician 40.00 0.00 256731 0 20358 Raul Bastarrachea Senior Scientist 40.00 0.00 190250 0 26069 Ellen Goodstein Executive Dir. 40.00 0.00 X 186077 0 10171 Kristen Nelson Clinical Nurse Pra 40.00 0.00 145861 0 15211 Mei Mei Church Nurse Practitioner 40.00 0.00 125656 0 7192 Alexander M DePaoli MD President 4.00 0.00 X X 14975 0 0 Kenneth S Waxman MD FACS Vice President 2.00 0.00 X X 0 0 0 James Sloan Treasurer 2.00 0.00 X X 0 0 0 Brad Webb PhD Secretary 2.00 0.00 X X 0 0 0 Joan Doell Arnold Trustee 1.00 0.00 X 0 0 0 Daniel N Berger MD Trustee 1.00 0.00 X 0 0 0 Anthony Castillo Trustee 1.00 0.00 X 0 0 0 George Emerson Trustee 1.00 0.00 X 0 0 0 Miguel Avila Trustee 1.00 0.00 X 0 0 0 Kathryn Brewer Trustee 1.00 0.00 X 0 0 0 Lindsey Duca PhD Trustee 1.00 0.00 X 0 0 0 Elena Engel Trustee 1.00 0.00 X 0 0 0 Deborah Gibson RD CDE Trustee 1.00 0.00 X 0 0 0 Norman Kurland Trustee 1.00 0.00 X 0 0 0 Michael Paskin Trustee 1.00 0.00 X 0 0 0 Matthew Rowe CIMA Trustee 1.00 0.00 X 0 0 0 Mark Simon Trustee 1.00 0.00 X 0 0 0 Steven Jung Esq Trustee 4.00 0.00 X 0 0 0 Flint Ogle Trustee 1.00 0.00 X 0 0 0 Miguel Rodriguez Trustee 1.00 0.00 X 0 0 0 Wendy Thies Sell Trustee 1.00 0.00 X 0 0 0 1233171 109735 6 false true false Samuel Klein 38 Ridgemoor Drive Clayton MO 63105 141600 Anchor Point IT Solutions 213 Santa Barbara St Santa Barbara CA 93101 IT Consulting 101830 2 588002 4677572 1232482 5265574 Patient Care Fees 541700 46125 46125 Research Contracts 541700 2524311 2524311 2570436 353871 353871 0 6256 6256 32162 32162 32162 32162 892896 911058 -18162 -18162 -18162 109800 588002 171029 -61229 -61229 0 0 Other 541700 5504 5504 5504 8154412 2589940 298898 0 0 0 0 817692 629622 109571 78499 0 2557636 1955766 277182 324688 89195 60364 14398 14433 186687 131536 28393 26758 241981 182219 31844 27918 0 11610 11610 22000 22000 0 0 27832 27832 396520 278660 91218 26642 53507 3313 1611 48583 92296 41401 21376 29519 202461 99101 62037 41323 2085 2085 149040 91820 40611 16609 43866 36801 2532 4533 0 39943 30745 6474 2724 0 0 98491 72883 11819 13789 72721 47855 16938 7928 Subject Reimbursement 317829 317829 Lab Supplies 142501 142287 202 12 Campaign Expenses 103265 103265 0 5669158 4124287 777648 767223 348694 247231 4965337 4343578 1153706 2602222 444087 667147 0 0 0 0 60948 45457 4320841 3062451 1219647 1258390 9567267 8543672 0 0 0 3165374 4466884 20925060 22174581 434912 484434 50000 55 36018 731821 520930 1216310 X 9847364 9340642 10556766 11617629 20404130 20958271 20925060 22174581 2485254 -1931113 X false true X true false X 1517367 1271673 2537565 3496686 5265574 14088865 2199541 2743021 3194510 3210241 2680236 14027549 0 0 0 3716908 4014694 5732075 6706927 7945810 28116414 3213419 3213419 0 3213419 3213419 24902995 199274 287851 193494 435645 353871 1470135 0 199274 287851 193494 435645 353871 1470135 0 27769 35731 21359 5852 5504 96215 3943951 4338276 5946928 7148424 8305185 29682764 0.83900 0.70330 0.04950 0.05500 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 4138658 5000 -344945 242467 3556246 4026624 413732 301698 4138658 3839382 406505 219263 4026624 3251175 588207 3839382 5304125 3300 -105039 200000 5002386 0.89000 0.11000 false false false 351758 351758 3571720 2803388 768332 270477 259063 11414 126886 126886 1258390 Assets Held in Split Interest Agreements 1990586 Beneficial Interest in Perpetual Trust 1384692 Cash Surrender Value of Life Insurance 126230 Non-Trustee Remainder Interest in Trust 934392 Other Receivable 30984 4466884 Obligations Under Split Interest Agreeme 731821 731821 X 6195467 -1382464 -548649 -1931113 8126580 27832 27832 8154412 5641326 5641326 27832 27832 5669158 Part V, Line 4: Intended uses of the endowment fund. SDRI has a policy of appropriation for distribution each year a prudent portion of earnings from endowment assets. In establishing this policy, SDRI considered the long-term expected return on its endowment. accordingly, over the long-term, SDRI expects its spending policy to allow SDRI to conduct diabetes research. This is consistent with SDRI's objective to maintain the purchasing power of the endowment assets held in perpetuity as well as to provide additional real growth the new gifts. Part X : FIN48 Footnote SDRI is organized as a California nonprofit corporation and has been recognized by the IRS as exempt from federal income taxes under Internal Revenue Code (IRC)Section 501(a) as an organization described in IRC Section 501(c)(3) and qualifies for the charitable contribution deduction under IRC Section 170(b)(1)(A)(vi) and has been determined not to be a private foundation under IRC Section 509(a)(2). SDRI is annually required to file a Return of Organization Exempt from Income Tax (Form990) with the IRS. In addition, SDRI is subject to income that is derived from business activities that are unrelated to its exempt purpose. Management has determined SDRI is not subject to unrelated business income tax and has not filed an Exempt Organization Business Income Tax Return (Form 990-T) with the IRS.SDRI tax filings are subject to examination by the IRS, generally for three years after they are filed. SDRI is not aware of any activities that would jeopardize its tax exempt status. X X X X X X X true 75th & 100th Anniversary Gals 697802 588002 109800 11239 98389 31264 30137 697802 588002 109800 11239 98389 31264 30137 171029 -61229 X X false false false false false false false false false David Kerr Director of Research & Innovation 313621 30734 344355 Ellen Goodstein Executive Dir. 186077 9304 867 196248 Kristen Nelson Clinical Nurse Pra 145861 7496 7715 161072 Kristin Castorino DO Research Physician 256731 12962 7396 277089 Raul Bastarrachea Senior Scientist 190250 10000 16069 216319 Alexander M DePaoli MD Board Member 14975 Patient Care false X 1 20488 FMV X 1 1200000 Appraised Value X Other 11994 Est FMV false false false Form 990, Part VI, Section B, Line 11b A draft of the Form 990 is sent to each board member prior to the designated board meeting during which it will be discussed. The Form 990 is discussed at the designated board meeting and must be approved by a majority of the board before being filed.If the board is not scheduled to meet until after the filing deadline, a board representative will review a draft of the Form 990 and make a recommendation for filing. The draft form 990 will then be reviewed by the entire board at the next scheduled meeting. Form 990, Part VI, Section B, Line 12c Each board member is asked to complete a conflict of interest form annually, which is reviewed by the objectivity and integrity in science committee (OISC). The OISC also reviews all research projects, publications, and scientific reports for conflicts of interest. Form 990, Part VI, Section B, Line 15a TThe Board of Trustees has established a Compensation Committee whose role is to provide the Board with Compensation recommendations for the Executive Director, Chief Scientific Officer, Chief Financial Officer, and any other highly compensated employees and consultants earning $200,000 or more per annum. The process for review and approval of compensation occurs upon initial hiring, whenever the term of employment is renewed or extended, and whenever the compensation is modified, unless a modification of compensation extends to substantially all employees. The President of the Board of Trustees is responsible for overseeing and evaluating executive performance on an annual basis. The supervisors of the highly compensated employees and consultants evaluate their performance. The Compensation Committee uses the following process to determine the compensation they will recommend to the board for approval for the executives and highly compensated employees and consultants: 1. Conduct research and obtain appropriate comparability or benchmarking data documenting compensation levels and benefits for similarly qualified individuals in comparable positions at similar organizations. Data may include salary and benefit compensation studies by independent sources, industry surveys, written job offers for positions at similar organizations, and information obtained from IRS Form 990 filings of similar organizations. 2. Carefully consider the performance reviews and supervisors recommendations regarding appropriate compensation.3. Determine the compensation to be recommended to the Board for approval, and contemporaneously document the basis for these recommendations, including the data on which it relied, the date it was discussed, the members present for the discussion, and the results of the vote.4. Present the Committees compensation recommendations to the full Board for approval, with approval documented in the minutes of the Board. Form 990, Part VI, Section B, Line 15b The Board of Trustees has established a Compensation Committee whose role is to provide the Board with Compensation recommendations for the Executive Director, Chief Scientific Officer, Chief Financial Officer, and any other highly compensated employees and consultants earning $200,000 or more per annum. The process for review and approval of compensation occurs upon initial hiring, whenever the term of employment is renewed or extended, and whenever the compensation is modified, unless a modification of compensation extends to substantially all employees. The President of the Board of Trustees is responsible for overseeing and evaluating executive performance on an annual basis. The supervisors of the highly compensated employees and consultants evaluate their performance. The Compensation Committee uses the following process to determine the compensation they will recommend to the board for approval for the executives and highly compensated employees and consultants: 1. Conduct research and obtain appropriate comparability or benchmarking data documenting compensation levels and benefits for similarly qualified individuals in comparable positions at similar organizations. Data may include salary and benefit compensation studies by independent sources, industry surveys, written job offers for positions at similar organizations, and information obtained from IRS Form 990 filings of similar organizations. 2. Carefully consider the performance reviews and supervisors recommendations regarding appropriate compensation.3. Determine the compensation to be recommended to the Board for approval, and contemporaneously document the basis for these recommendations, including the data on which it relied, the date it was discussed, the members present for the discussion, and the results of the vote.4. Present the Committees compensation recommendations to the full Board for approval, with approval documented in the minutes of the Board. Form 990, Part VI, Section C, Line 19 Governing documents and conflict of interest policy are available to the general public upon written request. In addition, the most recent audited financial statements and donor privacy policy are posted on the organization's website.